LeonaBio Inc LONA
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-09-18 |
| Shares Out. | 9,390,000 |
| Website | leonabio.com/ ↗ |
| Phone | 13026365400 |
| Employees | 19 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$19.0M |
| Free Cash Flow | -$61.9M |
| Total Assets | $56.9M |
| Total Liabilities | $23.3M |
| Equity | $33.6M |
About LeonaBio Inc
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
LeonaBio Inc is a publicly traded company under the ticker symbol LONA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)